Short answer

Prioritize the development of therapeutic agents that not only achieve efficacy but also actively mitigate common adverse effects, thereby enhancing patient compliance and quality of life.

Field: Innovation & Design
Source: British Journal of Pharmacology (2023)
Method: Pharmacological testing in animal models
Evidence: Strong effect

New endomorphin analogues, CEMR-1 and CEMR-2, demonstrate significant and long-lasting pain relief at the spinal level with a notably improved side effect profile compared to traditional opioids. This innovation & design research insight is drawn from a 2023 study published in British Journal of Pharmacology. Using Pharmacological testing in animal models, researchers explored how this design variable affects real-world outcomes. The key design takeaway: Prioritize the development of therapeutic agents that not only achieve efficacy but also actively mitigate common adverse effects, thereby enhancing patient compliance and quality of life.

Study

Innovation & DesignRecentStrong effect

Novel Analgesics Offer Potent Pain Relief with Reduced Side Effects

New endomorphin analogues, CEMR-1 and CEMR-2, demonstrate significant and long-lasting pain relief at the spinal level with a notably improved side effect profile compared to traditional opioids.

British Journal of Pharmacology · 2023

Key Findings

01Spinal administration of CEMR-1 and CEMR-2 produced potent and prolonged antinociceptive effects in acute pain models.
02Both analogues demonstrated significant analgesic activities in neuropathic, inflammatory, visceral, and formalin pain at the spinal level.
03CEMR-1 exhibited non-tolerance-forming analgesic properties, while CEMR-2 showed substantially reduced antinociceptive tolerance.
04CEMR-1 and CEMR-2 displayed no or reduced opioid-like side effects.

Application

Design takeaway

Prioritize the development of therapeutic agents that not only achieve efficacy but also actively mitigate common adverse effects, thereby enhancing patient compliance and quality of life.

How to apply

In the design of new pharmaceuticals or medical devices for pain management, consider the long-term impact on patient well-being and the potential for tolerance development.

Project actions

01When researching existing solutions, look for innovations that address the drawbacks of current technologies.
02Consider how user feedback and side effect profiles can inform the iterative design process.

Method & Evidence

AimTo evaluate the antinociceptive properties, tolerance development, and side effect profile of novel endomorphin analogues CEMR-1 and CEMR-2 following intrathecal administration.

MethodPharmacological testing in animal models

ProcedureCEMR-1 and CEMR-2 were administered intrathecally to assess their effects on various pain models (acute radiant heat, neuropathic, inflammatory, visceral, formalin). Antinociceptive tolerance was evaluated, and side effects such as conditioned place preference, physical dependence, locomotor activity, and gastrointestinal transit were measured.

ContextPharmaceutical research and development for pain management

Variables

IVAdministration of CEMR-1 and CEMR-2 (and their doses)

DVAntinociceptive effects, development of tolerance, side effects (conditioned place preference, physical dependence, locomotor activity, gastrointestinal transit)

CVPain models used, administration route (intrathecal), animal species, environmental conditions

Strengths & Limitations

Strengths

+Comprehensive evaluation across multiple pain models.
+Assessment of both efficacy and side effect profiles.

Limitations

The study was conducted on animals, so the results might differ in humans. The long-term effects of these specific analogues are not fully known.

Reliability & validity

The study uses multiple pain models and assesses various side effects, which enhances the validity of the findings. Reliability would depend on the reproducibility of these results in independent studies.

Think critically

How can the principles of designing for reduced side effects in pharmaceuticals be applied to the design of other user-facing technologies, such as wearable health trackers or assistive devices?

Design Principles

"Efficacy with minimal adverse effects is paramount in therapeutic design."

This research introduces potential breakthroughs in pain management by developing compounds that target pain pathways effectively while minimizing undesirable side effects. For designers, this highlights the ongoing pursuit of therapeutic innovation, where understanding molecular mechanisms can lead to the creation of more effective and user-friendly medical solutions.

What This Means for Your Design

Scientists have created new pain-relief drugs that work really well in the spine and don't cause the usual problems like addiction or constipation.

How to use in your project

1.Reference this study when discussing the importance of user well-being and minimizing negative impacts in the design of medical products or therapeutic interventions.

Add to My Project

Quick Cite

Paragraph starter

Research into novel endomorphin analogues CEMR-1 and CEMR-2 has demonstrated their potent and long-lasting antinociceptive effects at the spinal level with a favourable side effect profile, suggesting a significant advancement in pain management design.

Source

British Journal of Pharmacology

Novel endomorphin analogues CEMR‐1 and CEMR‐2 produce potent and long‐lasting antinociception with a favourable side effect profile at the spinal level

journal · 2023

View source

Questions About This Research

What does the research say about novel analgesics offer potent pain relief with reduced side effects?: Prioritize the development of therapeutic agents that not only achieve efficacy but also actively mitigate common adverse effects, thereby enhancing patient compliance and quality of life. Evidence: British Journal of Pharmacology (2023).
Why does "Novel Analgesics Offer Potent Pain Relief with Reduced Side Effects" matter for design?: This research introduces potential breakthroughs in pain management by developing compounds that target pain pathways effectively while minimizing undesirable side effects. For designers, this highlights the ongoing pursuit of therapeutic innovation, where understanding molecular mechanisms can lead to the creation of more effective and user-friendly medical solutions.
How can designers apply this research?: Prioritize the development of therapeutic agents that not only achieve efficacy but also actively mitigate common adverse effects, thereby enhancing patient compliance and quality of life.
What were the main findings?: Spinal administration of CEMR-1 and CEMR-2 produced potent and prolonged antinociceptive effects in acute pain models.. Both analogues demonstrated significant analgesic activities in neuropathic, inflammatory, visceral, and formalin pain at the spinal level.. CEMR-1 exhibited non-tolerance-forming analgesic properties, while CEMR-2 showed substantially reduced antinociceptive tolerance.. CEMR-1 and CEMR-2 displayed no or reduced opioid-like side effects.
What research method was used?: Pharmacological testing in animal models.
How strong is the evidence?: Evidence strength is rated Strong effect, based on a 2023 journal from British Journal of Pharmacology.
What should I do differently in my next project?: In the design of new pharmaceuticals or medical devices for pain management, consider the long-term impact on patient well-being and the potential for tolerance development.
What are the limitations?: Findings are based on animal models and may not directly translate to human responses. Further clinical trials are necessary.